Drug research

Cadisegliatin 800 mg QD

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as TTP399

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsNCT07616206	vTv Therapeutics	Phase 2	Not yet recruiting	2027-06Estimated
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133	vTv Therapeutics	Phase 3	Active not recruiting	2027-04Estimated

vTv TherapeuticsNot yet recruitingPrimary completion: 2027-06 · Estimated

Trial details

vTv TherapeuticsActive not recruitingPrimary completion: 2027-04 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.